Ascites Clinical Trial
Official title:
Does Point of Care Ultrasound Change Needle Insertion Location During Routine Bedside Paracentesis?
NCT number | NCT04245553 |
Other study ID # | 6028481 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | February 7, 2020 |
Est. completion date | March 1, 2021 |
Verified date | April 2024 |
Source | Queen's University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Paracentesis is a bedside procedure in which a needle is inserted into a patient's peritoneum in order to obtain ascitic fluid. This is a safe bedside procedure with very low risks of complications that is usually performed using physical exam maneuvers to determine the site of needle insertion. Point of care ultrasound (POCUS) technology has improved the safety of central venous catheter insertion and thoracentesis, yet the data on safety in paracentesis is equivocal. In a practical study, we aim to determine if POCUS will change the needle insertion site over the traditional anatomic landmarking method. Operators will landmark for paracentesis using conventional physical exam and then utilize POCUS to determine if there is a more optimal site. The primary endpoint will be whether POCUS yielded a change in the needle insertion site, as defined by a location greater than 5cm from the anatomic site, at least 20% of the time. The results will further our understanding of POCUS in improving procedural safety, thereby adding to the currently limited literature on this topic. Furthermore, this study will inform residency training programs about the utility in POCUS training for paracentesis and may advocate for the availability of POCUS devices to physicians performing this procedure.
Status | Completed |
Enrollment | 45 |
Est. completion date | March 1, 2021 |
Est. primary completion date | March 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility | This is in effort to capture routine paracentesis cases. Inclusion Criteria: - Participants scheduled to have either a diagnostic of therapeutic paracentesis. - Participants can be either inpatients under the care of general internal medicine, or outpatients under the care of gastroenterology or general internal medicine. - Operators will be recruited on a volunteer basis and will include medical residents or subspecialty fellows with knowledge of POCUS for paracentesis purposes, either through core residency programs or more advanced training. Exclusion Criteria: - Loculated ascites - Current anticoagulation - Hemodynamic instability - Bowel obstruction - Pregnancy - Abdominal wall cellulitis - Platelet count <20 |
Country | Name | City | State |
---|---|---|---|
Canada | Kingston Health Sciences Center | Kingston | Ontario |
Lead Sponsor | Collaborator |
---|---|
Steven Montague |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Preference of land-marking method | Does the clinician performing the procedure prefer the needle insertion site found using point of care ultrasound, or using the traditional anatomic method. A clinically significant difference in location is defined as greater than or equal to 5cm apart. If the difference in locations is not at least 5cm apart, this will be defined as no preference in land-marking methods. | Determined immediatly after the POCUS landmarking is done. | |
Secondary | Depth of Ascitis | Depth of ascitis, measured perpendicular to the overlying skin, at the location land-marked using traditional anatomic method, versus the location found with point of care ultrasound. | Determined immediatly after the POCUS landmarking is done. | |
Secondary | Immediate Complications | The overall rate of any complications observed while performing the procedure. This includes bleeding, perforation/puncture of any internal organ, or a failed attempt. | Occuring at any time between the needle insertion and removal of the paracentesis drain. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02891642 -
Liquid Biopsy With Immunomagnetic Beads Capture Technique for Malignant Cell Detection in Body Fluid
|
||
Recruiting |
NCT00239096 -
Prevention of Decompensation in Liver Cirrhosis
|
Phase 4 | |
Active, not recruiting |
NCT03973866 -
Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study)
|
N/A | |
Terminated |
NCT01455246 -
Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis
|
Phase 2/Phase 3 | |
Completed |
NCT01349348 -
Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites
|
Phase 3 | |
Completed |
NCT01578226 -
Procalcitonin in Cirrhotic Patients at High Risk for Sepsis
|
N/A | |
Terminated |
NCT00548366 -
Sodium Restriction in the Management of Cirrhotic Ascites
|
Phase 4 | |
Recruiting |
NCT05025878 -
13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.
|
||
Completed |
NCT03327688 -
Point-of-care Ultrasound in Finland
|
N/A | |
Not yet recruiting |
NCT04550091 -
Role Of Multi-detector Computed Tomography In Differentiation Between Different Types Of Ascites
|
||
Not yet recruiting |
NCT01716611 -
Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites
|
Phase 4 | |
Completed |
NCT01769040 -
Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis
|
Phase 4 | |
Recruiting |
NCT05700708 -
Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Refractory Ascites
|
||
Recruiting |
NCT05511766 -
Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis
|
Phase 2/Phase 3 | |
Completed |
NCT05013502 -
Empagliflozin in Diuretic Refractory Ascites
|
Phase 1 | |
Not yet recruiting |
NCT06436807 -
PMCF Study of the CE-marked Drainova® ArgentiC Catheter
|
||
Completed |
NCT03263598 -
Validation of Diagnostic Usefulness of the Random Urine Na/K Ratio for Replacement of 24hr Urine Na Excretion in Cirrhotic Patients With Ascites
|
||
Completed |
NCT00907673 -
The Automated Fluid Shunt (AFS)in Chronic Congestive Heart Failure
|
N/A | |
Terminated |
NCT00796861 -
Trial of Sunitinib for Refractory Malignant Ascites
|
Phase 2 | |
Suspended |
NCT00511394 -
Acute Hemodynamics of Albumin Versus Normal Saline in Cirrhosis
|
N/A |